Eden Research plc, a company focused on sustainable biopesticides and plastic-free formulation technology, has provided an update on its Capital Raising. The company expects to complete the Second Admission and Conditional Capital Raising shortly, as the first three conditions have been met. The Placing of the Conditional Placing Shares is conditional on the approval of the Resolutions at the General Meeting, obtaining Advanced Assurance from HMRC, the Capital Reduction becoming effective, and Second Admission. Eden Research develops and supplies biopesticide products and natural microencapsulation technologies to the global crop protection, animal health, and consumer products industries. The company's products are formulated with terpene active ingredients, based on natural plant defense metabolites. Eden has two products currently on the market: Mevalone, a foliar biofungicide, and Cedroz, a bionematicide. Eden's Sustaine encapsulation technology is used to enhance the performance and ease-of-use of natural and synthetic compounds. Eden Research was admitted to trading on AIM in 2012 and derives 100% of its total annual revenues from sustainable products and services.